Isomer ratios and mean angular momenta of photonuclear reaction products

Isomer ratios and mean angular momenta are obtained both for photofission products of 237Np, 238U and for nuclei 122,120m,gSb and 117m,gIn. Photonuclear reactions 121Sb(γ,n)120m,gSb, 123Sb(γ,n)122m,gSb, 118Sn(γ,p)117m,gIn were studied in the last cases. The technique of gamma-ray spectrometry for isomeric ratio determination was used. Target nuclei were irradiated by bremsstrahlung spectrum of microtron M-30. Comparison of isomer ratios calculated by Empire II code with experimental data was performed. Effects of the nuclear structure model parameters on values of isomer ratios are discussedДосліджено ізомерні відношення та визначено середні кутові моменти для продуктів фотоділення ядер 238U і 237Np, а також виміряні ізомерні відношення для ядер 120,122m,gSb и 117m,gIn в реакціях (γ,n) та (γ,p). Опромінення проводилося гальмівними γ-квантами мікротрону М-30 з максимальною енергією спектру 16 та 15 МеВ. Досліджено залежності ізомерних відношень від кутових моментів збуджених ядер з використанням програми Empire II для розрахунку характеристик ядерних реакцій.Измерены изомерные отношения и извлечены средние угловые моменты для продуктов фотоделения ядер 238U и 237Np, а также измерены изомерные отношения для ядер 120,122m,gSb и 117m,gIn в реакциях (γ,n) и (γ,p). Облучение проводилось тормозными γ-квантами микротрона М-30 с максимальной энергией спектра 16 и 15 МэВ. Исследованы зависимости изомерных отношений от угловых моментов возбужденных ядер с использованием программы Empire II для расчета характеристик ядерных реакций

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362